Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2429 | Monodose RS01 Wiki | 1.00 |
| drug1616 | GSK3923868 Wiki | 1.00 |
| drug2296 | Matching placebo Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001249 | Asthma NIH | 0.28 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.26 |
| D053120 | Respiratory Aspiration NIH | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002099 | Asthma HPO | 0.28 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.26 |
Navigate: Correlations HPO
There is one clinical trial.
This is a randomized, placebo-controlled study to assess the safety, PK profile, and efficacy of COVI-AMG in subjects with COVID-19.
Description: Safety as assessed by incidence of adverse events by type, frequency, severity, and causality
Measure: Incidence of adverse events by type, frequency, severity, and causality (safety) Time: Randomization through study completion at Day 60Description: Safety as assessed by incidence of treatment-emergent adverse events by type, frequency, severity, and causality
Measure: Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety) Time: Randomization through study completion at Day 60Description: Safety as assessed by incidence of serious adverse events by type, frequency, severity, and causality
Measure: Incidence of serious adverse events by type, frequency, severity, and causality (safety) Time: Randomization through study completion at Day 60Description: Safety as assessed by incidence of dose-limiting toxicities
Measure: Incidence of dose-limiting toxicities (safety) Time: Randomization through study completion at Day 60Description: Safety as assessed by incidence of clinically meaningful laboratory abnormalities
Measure: Incidence of clinically meaningful laboratory abnormalities (safety) Time: Randomization through study completion at Day 60Description: Viral load as assessed using plasma and salivary samples at various timepoints correlated with nasopharyngeal testing
Measure: Viral load as assessed using plasma and salivary samples at various timepoints Time: Randomization through study completion at Day 60Description: Time from onset of COVID-19 symptoms to treatment (Day 1)
Measure: Time from onset of COVID-19 symptoms to treatment (Day 1) Time: Day 1Description: Presence and levels of anti-drug antibodies directed to COVI-AMG
Measure: Presence and levels of anti-drug antibodies directed to COVI-AMG Time: Randomization through study completion at Day 60Description: Cytokine levels post-treatment including EGF, IFNγ, IL-1β, IL-6, IL-8, IL-10, and TNFα will be measured by ELISA
Measure: Cytokine levels post-treatment Time: Randomization through study completion at Day 60Description: Area under the serum concentration-time curve (AUC) of COVI-AMG
Measure: AUC of COVI-AMG (PK) Time: Randomization through study completion at Day 60Description: Maximum observed serum concentration (Cmax) of COVI-AMG
Measure: Cmax of COVI-AMG (PK) Time: Randomization through study completion at Day 60Description: Time to Cmax (Tmax) of COVI-AMG
Measure: Tmax of COVI-AMG (PK) Time: Randomization through study completion at Day 60Description: Apparent serum terminal elimination half life (t½) of COVI-AMG
Measure: t½ of COVI-AMG (PK) Time: Randomization through study completion at Day 60Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports